Down But Not Out, Ranbaxy Eyes Generics Blockbuster Launches In China
This article was originally published in PharmAsia News
Executive Summary
Fierce competition makes China a tough nut to crack for generics, something India’s largest drug manufacturer Ranbaxy says it has learned the hard way, but after walking away from a joint venture, the firm is ready to try again.